NetworkNewsBreaks

WednesdayJun 05, 2019 3:14 pm

NetworkNewsBreaks – Earth Science Tech Inc. (ETST) Infomercial Features Real-life Success Story

Florida-based biotech company Earth Science Tech (OTCQB: ETST) recently began an informercial campaign that tells the real-life story of the impact of ETST cannabinoids on a consumer. A recent article discussing the company reads, “The infomercial is introduced by Kevin Harrington, identified as an original shark on the TV show Shark Tank. He explains that ETST’s full-spectrum cannabinoids can help the ‘aches or pains’ issue (http://nnw.fm/qOcc5). The spot then tells the success story of real-life customer Rhoda Friedman, who credits her improvement in mobility and lifestyle to ETST’s full-spectrum cannabinoids. As the infomercial ends, viewers are invited to buy ETST products,…

Continue Reading

WednesdayJun 05, 2019 2:47 pm

NetworkNewsBreaks – Spectrum Global Solutions Inc. (SGSI) Achieves First Quarter Positive Income

Spectrum Global Solutions (OTCQB: SGSI), a leading telecommunications engineering and infrastructure services provider, recently reported its first quarter with positive income from operations. An article discussing SGSI’s Q1 2019 financial results reads, “For the three months ended March 31, 2019, SGSI reported revenues of $11,335,732, as compared to sales of $4,327,764 the first quarter of 2018. In 2019, the company showed its first quarterly income from continuing operations of $14,699, as compared to a loss from operations of $743,491 during the same period in 2018 (http://nnw.fm/WQc71). . . . ‘Revenue was just over $11.3 million, which reflects consistent growth in our…

Continue Reading

WednesdayJun 05, 2019 2:41 pm

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Developing Gene Therapy-based Approach to Treat Non-small Cell Lung Cancer

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is developing Oncoprex immunogene therapy as an innovative, gene therapy-based approach for the treatment of non-small cell lung cancer (“NSCLC”). An article further discussing the company reads, “NSCLC is the most common type of lung cancer. It accounts for approximately 85% of all lung-cancer cases, and despite the development of innovative treatment strategies, the survival rate for lung cancer patients has not improved significantly over the past 25 years (http://nnw.fm/0YVIu) . . . . Breakthrough technologies and therapeutic approaches like those developed by Genprex could take cancer treatment solutions to a new level of…

Continue Reading

WednesdayJun 05, 2019 10:41 am

NetworkNewsBreaks – Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) Renews Access Agreements for Port and Power

Canadian iron ore exploration and development company Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) this morning announced the renewal of its letter of intent (“LOI”) with TransInvestServis (“TIS”) for storage and cape-size ship loading capacity at TIS’ privately owned berth at Port Yuzhny in an effort to match projected production from the phased build of Black Iron’s Shymanivske Project. In addition, the company has renewed its LOI with DTEK DNIPRO GRIDS JSC to secure the required electricity to operate the mine and processing plant. “Renewal of our major infrastructure LOIs is important to provide confidence for investors in…

Continue Reading

WednesdayJun 05, 2019 10:04 am

NetworkNewsBreaks – Golden Developing Solutions Inc. (DVLP) Announces Official Move-In Date for Denver Production Facility

Emerging leader in the cannabis, hemp and cannabidiol (CBD) marketplace Golden Developing Solutions Inc. (OTC: DVLP) this morning announced June 10, 2019, as the official date that the company will move into its new 25,000-square-foot production facility in Denver, Colorado. According to the update, a new financing agreement is funding equipment to outfit the facility, and the company anticipates a five-fold increase in total production levels in the first three months following delivery and installation. “We are excited to get into the new facility, get organized, and ramp up operations,” DVLP CEO Stavros Triant stated in the news release. “This…

Continue Reading

WednesdayJun 05, 2019 9:53 am

NetworkNewsBreaks – Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Launches QuadSight Demonstration Center

Automotive technology innovator Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) this morning announced the opening of its innovative demonstration center. Per the update, the QuadSight demonstration center, located near the company's offices, provides investors, customers and business partners with the opportunity to ride in a vehicle that’s equipped with Foresight’s automotive vision system. The advanced demonstration equipment simulates rain, fog, glare and complete darkness, enabling participants to see and experience, in real time, QuadSight’s obstacle detection capabilities in extreme weather and lighting conditions. “We are proud to launch our innovative demonstration center in Israel to investors and partners,” Foresight…

Continue Reading

WednesdayJun 05, 2019 9:28 am

NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) to Showcase Alzheimer’s Drug Candidate XPro1595 at TNF Conference

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, on Tuesday announced that its director of neuroscience, CJ Barnum, Ph.D., will be giving a scientific talk and presenting a poster on Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, 2019. According to the update, “A Phase 1b biomarker-directed study to target soluble tumor necrosis factor in Alzheimer’s (“AD”) patients,” is the title of the poster and talk in which Barnum will discuss INmune Bio’s clinical approach to treating Alzheimer’s disease. “XPro1595 has been represented…

Continue Reading

TuesdayJun 04, 2019 1:47 pm

NetworkNewsBreaks – InterDigital, Inc. (NASDAQ: IDCC) Closes $400M Senior Convertible Notes Offering

InterDigital (NASDAQ: IDCC) has closed a $400 million offering of 2.00% Senior Convertible Notes. Per the update, the notes are due in 2024 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The offering of $400 million includes $50 million in aggregate principal amount of the notes issued per the full exercise of the over-allotment option. The notes will be senior unsecured obligations of InterDigital and will pay interest, at a rate of 2.00% per year, semi-annually in cash on June 1 and December 1, and will mature on June 1, 2024. ROTH…

Continue Reading

TuesdayJun 04, 2019 1:40 pm

NetworkNewsBreaks – Prescient Therapeutics Ltd. (ASX: PTX) Completes $7 Million AUD PIPE

Clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) has completed a $7 Million AUD PIPE with institutional and sophisticated investors. According to the update, the placement involved the issue of approximately 140 million shares, each at $0.05, largely to institutional investors. ROTH Capital Partners acted as U.S. placement agent for the transaction. “Prescient is delighted with the support from its existing shareholders, and is very pleased to welcome new shareholders to the Company, including new US and Australian institutional investors with particular expertise in life science investing,” PTX CEO Steven Yatomi-Clarke said in the news release. “It is encouraging…

Continue Reading

TuesdayJun 04, 2019 1:00 pm

NetworkNewsBreaks – The Lovesac Company (NASDAQ: LOVE) Secures $103.5M Through Underwritten Public Offering

The Lovesac Company (NASDAQ: LOVE) has completed an underwritten public offering of 2,875,000 shares of its common stock. According to the update, the offering resulted in gross proceeds of approximately $103.5 million, which Lovesac intends to use for increased sales and marketing expenses, product development, working capital and other general corporate purposes. The offering consisted of 750,000 Lovesac-offered shares and 2,125,000 shares by certain selling stockholders of Lovesac, including 375,000 shares per the full exercise of the over-allotment option. The shares were sold at the public offering price of $36.00 per share. ROTH Capital Partners acted as joint book-running manager…

Continue Reading